Myriad Genetics reports second quarter 2026 financial results
Revenue fell 11% year-over-year to $190.7 million, with initiatives to improve efficiency and scalability.
See the latest news and media coverage for Myriad. We track all announcements, press releases, and industry mentions in real time, all in one place.
Genetic testing company
myriad.comLast updated
In short: Myriad expanded its oncology and prenatal testing portfolios, integrated AI technologies, and secured strategic global partnerships.
Revenue fell 11% year-over-year to $190.7 million, with initiatives to improve efficiency and scalability.
The company will hold an earnings conference call at 4:30 pm ET on July 30 after market close, providing financial overview and business update.
The test runs four prenatal genetic screens simultaneously from one blood draw as early as eight weeks gestation.
Findings from 14 studies involving 8,478 patients support risk stratification beyond conventional clinical tools.
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 46.1% in the afternoon session after the company reported disappointing...
Myriad Genetics lowered its full-year revenue guidance, as second quarter sales fell due to volume challenges in prenatal health and increased payer friction. The genetic...
Myriad (MYGN) delivered earnings and revenue surprises of -733.33% and -7.12%, respectively, for the...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
Track Myriad and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Myriad and other trending companies.